Guizhou Sanli Pharmaceutical Stalls as China’s Innovation‑Led Stocks Soar
Guizhou Sanli Pharmaceutical’s flat stock and steep monthly decline show why China’s investors favor innovation‑led pharma and tech, not traditional drug makers.
3 minutes to read